You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aminomethyl benzamides as novel anti Ebola agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDEbola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminopiperidines as novel anti influenza agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDInfluenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Novel DHA Treatment Approach for Alzheimer's Disease
SBC: Orochem Technologies Inc. Topic: NIAAlzheimer’s disease (AD) and related dementia (ADRD) are adversely impacting the healthy lifespan in our aging population. Fish oil has been suggested to improve AD/ADRD outcomes. The omega 3 fatty acids (Om3FA) in fish oil in particular DHA (docosahexaenoic acid) is a key molecule. Some data exists that DHA is beneficial for protection against age related cognitive decline and related dementia ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy
SBC: ENDECTRA LLC Topic: 102PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations
SBC: PHOTOSONOX LLC Topic: NIBIBABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community
SBC: EPERTURE LLC Topic: NIAProject Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics
SBC: SCHEDULE 1 THERAPEUTICS INC Topic: NIDAOptimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics Project Summary: Migraine is a disorder that affects 15% of all people in the US, the majority of which are women. Migraine is one of the leading causes of missed days at work during which patients are unable to complete many daily activities. Currently approved treatments for migraine are not satisfying with at mos ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Prevention of GVHD by a probiotic exopolysaccharide.
SBC: HASENTECH, INC. Topic: NIAIDAbstract Graft versus host disease (GVHD) is an often lethal complication from allogeneic hematopoietic stem cell transplantation used as treatment for a variety of hematologic malignancies. GVHD results from an attack on host cells by alloreactive T cells of the donor. Standard prevention and treatment for GVHD is administration of broadly immunosuppressive drugs, which suppress alloreactive T ce ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Developing high throughput measurement of thiopurine in DNA by mass spectrometry
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 400PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of Optimized AAV Serotype Vectors for Human Gene Therapy
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health